Therapies for Children With Autism Spectrum Disorders

Evidence Table. Therapies for children with ASD (continued)
Study
Description Intervention
Author:
Granpeesheh
et al., 2009
Country:
US
Practice
setting:
Specialty treatment
center
Intervention
setting:
Community
Enrollment
period:
1995 to 2007
Funding:
NR
Author industry
relationship
disclosures:
None
Design:
Retrospective
case series
Author:
Handen, et al.,
2009
Country:
US
Practice
setting:
Academic
Intervention:
Early Intensive Behavioral
Intervention
Assessments:
WISC-R and WISC-III,
SB-FE, MPS, LIPS-R,
MESL (AGS edition),
BSID-II, DAS
Groups:
G1: intervention
Provider:
NR
Measure of treatment
fidelity reported: No
Co-interventions held
stable during treatment:
NR
Concomitant therapies:
NR
N at enrollment:
G1: 38
N at follow-up:
G1: 38
Intervention:
Randomized, doubleblind,
placebo-controlled,
parallel groups, involving
12 centers in the US.
Oral human immuneglobulin
(IGOH; Oralgam),
140, 420, or 840 mg/day
Inclusion/ Exclusion
Criteria/ Population
Inclusion criteria:
• No longer presented with
developmental delay in
any area of functioning
of which author is aware
• Placed in regular
education classrooms
and were earning
passing grades without
any special assistance
• Reason for discharge
from author’s treatment
was the absence of any
apparent need for
treatment
• Agreement of criteria
must be met between a
minimum of two senior
clinicians who were
familiar with the course
and outcome of a
patient’s treatment
• Patient record had to
contain cognitive testing
within 6 months of start
of ABA services and
within 6 months of
stopping ABA services
Exclusion criteria:
• See inclusion criteria
Age, months ± SD
(range):
G1: 40.32 ± 7.27 (24-55)
Mental age: NR
Gender: NR
Race/ethnicity: NR
SES:
Maternal education: NR
Household income: NR
Diagnostic approach:
Referral
Diagnostic tool/method:
NR
Diagnostic category, %:
Autism: 100
Other characteristics:
NR
Inclusion criteria:
• Met diagnostic criteria
for autism per DSM-IV,
corroborated by ADI-R
• CGI severity scale > 3
(autistic symptoms)
• History of chronic,
persistent GI disturbance
C-46
Baseline
Measures Outcomes
month follow-up (r
= 0.63; P < 0.01)†
Adaptive behavior:
VABS composite
score, mean ± SD
(range):
G1: 68.04 ± 7.79
(57-82)
Educational/
cognitive/
academic
attainment:
IQ, mean ± SD
(range):
G1: 83.6 ± 19.15
(50-133)
Adaptive
behavior:
VABS composite,
mean ± SD
(range):
G1: 88.87 ± 11.02
(69-111)
Educational/
cognitive/
academic
attainment:
IQ, mean ± SD
(range):
G1: 107.9 ± 9.59
(89-128)
Harms:
NR
Modifiers:
NR
Overall ratings:
CGI, physician
rated, n (%):
Very much or
much improved:
G1a: 3/29 (10.3)
G1b: 9/26 (34.6)
G1c: 5/28 (17.9)